1-3 of 3
Pavel Pisa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

Clinical Trials & Observations
Gilles Salles, Franck Morschhauser, Thierry Lamy, Noel Milpied, Catherine Thieblemont, Hervé Tilly, Gabi Bieska, Elina Asikanius, David Carlile, Joe Birkett, Pavel Pisa, Guillaume Cartron
Journal: Blood
Blood (2012) 119 (22): 5126–5132.
https://doi.org/10.1182/blood-2012-01-404368
Published: 2012
Journal Articles

A Phase I Study of GA101 (RO5072759) Monotherapy Followed by Maintenance in Patients with Multiply Relapsed/Refractory CD20 + Malignant Disease.

Laurie H. Sehn, MD, MPH, Sarit E. Assouline, MD, Douglas A. Stewart, MD, Joy Mangel, MD, FRCPC, Pavel Pisa, MD, PhD, Jaimal Kothari, MD, Michael Crump, MD
Journal: Blood
Blood (2009) 114 (22): 934.
https://doi.org/10.1182/blood.V114.22.934.934
Published: 2009
Journal Articles

Interferon α down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells

Dawei Xu, Sven Erickson, Michael Szeps, Astrid Gruber, Olle Sangfelt, Stefan Einhorn, Pavel Pisa, Dan Grandér
Journal: Blood
Blood (2000) 96 (13): 4313–4318.
https://doi.org/10.1182/blood.V96.13.4313
Published: 2000